🇺🇸 FDA

Intelligence · Clinical Pipeline

George Institute for Pipeline

All ClinicalTrials.gov programs at George Institute for — phase, modality, and trial IDs.

Programs
187

Quick answer

George Institute for has 187 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.

    phase 2 small molecule active

    1 trial

  2. Dasatinib/Teva 50 mg επικαλυμμένα με λεπτό υμένιο δισκία, Maltodextrine powder, SPRYCEL 20 mg film-coated tablets

    The George Institute

    Human immunodeficiency virus

    phase 2 small molecule active

    1 trial

  3. Doxycycline EG 200 mg Tabletten

    The George Institute

    Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphilis)

    phase 2 small molecule active

    1 trial

  4. EFAVIRENZ

    The George Institute

    Type C Niemann-Pick Disease

    phase 2 small molecule active

    1 trial

  5. ELIGARD 22,5 mg, poudre et solvant pour solution injectable

    The George Institute

    Intermediate risk prostate cancer

    phase 2 small molecule active

    1 trial

  6. ENCORAFENIB , CETUXIMAB

    The George Institute

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  7. ENDORET-PRGF

    The George Institute

    glaucoma

    phase 2 small molecule active

    1 trial

  8. EPLERENONE

    The George Institute

    Heart failure with reduced ejection fraction in combination with severe chronic kidney disease

    phase 2 small molecule active

    1 trial

  9. ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, MELPHALAN, VINCRISTINE TEVA 1 mg/ml, solution injectable, ALKERAN 50 mg poudre et solvant pour solution pour perfusion Melphalan

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  10. Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

    The George Institute

    Metastatic pancreatic adenocarcinoma

    phase 2 other active

    1 trial

  11. Erbitux 5 mg/mL solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, MVASI 25 mg/mL concentrate for solution for infusion, Braftovi 75 mg hard capsules

    The George Institute

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  12. FLUOROURACIL, JZP598, PEMBROLIZUMAB, FOLIC ACID, OXALIPLATIN

    The George Institute

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, S241656 film-coated tablet 50mg, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion, S241656 film-coated tablet 25mg, Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bugvi 5 mg/ml pulbere pentru dispersie perfuzabilă, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung,

    The George Institute

    Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mutations

    phase 2 small molecule active

    1 trial

  14. FRUZAQLA 5 mg hard capsules, Tevimbra 100 mg concentrate for solution for infusion, FRUZAQLA 1 mg hard capsules, Lonsurf 15 mg/6.14 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic Colorectal Cancer without liver metastases

    phase 2 small molecule active

    1 trial

  15. FULVESTRANT, M1774 50mg, M1774 30mg

    The George Institute

    advanced breast cancer

    phase 2 small molecule active

    1 trial

  16. Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  17. Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372

    The George Institute

    Subjects with advanced solid tumour

    phase 2 small molecule active

    1 trial

  18. GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

    The George Institute

    Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.

    phase 2 small molecule active

    1 trial

  19. GIOTRIF 40 mg film-coated tablets, GIOTRIF 30 mg film-coated tablets, GIOTRIF 20 mg film-coated tablets

    The George Institute

    Patients diagnosed with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx secondary to Fanconi anemia.

    phase 2 small molecule active

    1 trial

  20. Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion, Polivy 140 mg powder for concentrate for solution for infusion.

    The George Institute

    previously untreated aggressive B-cell lymphoma

    phase 2 small molecule active

    1 trial

  21. Grafalon 20 mg/ml koncentrát pro infuzní roztok

    The George Institute

    Type 1 diabetes

    phase 2 small molecule active

    1 trial

  22. Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  23. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  24. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  25. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  26. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  27. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  28. IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  29. IMLIFIDASE

    The George Institute

    kidney trasplant

    phase 2 small molecule active

    1 trial

  30. IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS

    The George Institute

    chronic kidney disease, Hypersensitized patients

    phase 2 other active

    1 trial

  31. INDOCYANINE GREEN

    The George Institute

    Patients with primary invasive early breast cancer (T1-T2) that will undergo planned breast-conserving surgery

    phase 2 small molecule active

    1 trial

  32. IVERMECTIN

    The George Institute

    Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.

    phase 2 small molecule active

    1 trial

  33. Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer

    The George Institute

    Ovarian Cancer

    phase 2 other active

    1 trial

  34. Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab

    The George Institute

    Adjuvant therapy after salvage surgery of high risk recurrent head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  35. JEMPERLI 500 mg concentrate for solution for infusion, Zejula 100 mg film-coated tablets

    The George Institute

    DNA repair-deficient or platinum-sensitive solid tumors

    phase 2 small molecule active

    1 trial

  36. KETOROLAC, PREGABALIN

    The George Institute

    Estrogen receptor-positive early breast cancer (ER + BC).

    phase 2 small molecule active

    1 trial

  37. KEYTRUDA 25 mg/mL concentrate for solution for infusion, ENDOXAN 1000 mg, poudre pour solution injectable, EPIRUBICINE MEDAC 2 mg/ml, solution pour perfusion, PACLITAXEL KABI 6 mg/ml, solution à diluer pour perfusion.

    The George Institute

    Breast cancer

    phase 2 small molecule active

    1 trial

  38. KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL

    The George Institute

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  39. KEYTRUDA 25 mg/mL concentrate for solution for infusion, S095029/Sym025

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  40. LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

    The George Institute

    Colon cancer

    phase 2 other active

    1 trial

  41. LENVIMA 4 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    advanced stage hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  42. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  43. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  44. LIBTAYO 350 mg concentrate for solution for infusion., IMUNOCARE 5% crema

    The George Institute

    Cutaneous Basal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  45. LUMYKRAS 120 mg film-coated tablets

    The George Institute

    locally-advanced and unresectable or metastatic NSCLC with KRAS G12C

    phase 2 small molecule active

    1 trial

  46. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  47. Lenvatinib, Belzutifan, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Patients with localized renal cell carcinoma

    phase 2 small molecule active

    1 trial

  48. Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    The George Institute

    Resectable mucosal melanomas

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does George Institute for have?

187 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.